MARKET

QGEN

QGEN

Qiagen
NYSE
42.01
+0.73
+1.77%
Pre Market: 43.34 +1.33 +3.17% 07:44 10/04 EDT
OPEN
41.92
PREV CLOSE
41.28
HIGH
42.23
LOW
41.70
VOLUME
3.70K
TURNOVER
--
52 WEEK HIGH
58.00
52 WEEK LOW
40.49
MARKET CAP
9.56B
P/E (TTM)
18.87
1D
5D
1M
3M
1Y
5Y
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Zacks · 1d ago
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Benzinga · 09/27 18:14
FDA updates COVID-19 test policy to cut emergency use requests
Revising its COVID-19 test policy, the U.S. Food and Drug Administration (FDA) said Tuesday that the agency would review only a small number of new emergency use authorization (EUA) requests for diagnostic tests.Instead, the FDA urges deve...
Seekingalpha · 09/27 15:47
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and
Benzinga · 09/23 12:02
QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses
QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.
Zacks · 09/19 16:27
IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
London-based privately-owned global investment company, IGI Inex Holding, today announces it has become a strategic investor in artificial intelligence (AI) and machine learning (ML) leaders, Munich-based AI asset and portfolio management company, quantumr...
ACCESSWIRE · 09/16 08:20
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
HILDEN, Germany & GERMANTOWN, Md., September 15, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses. The new assays for the identificat...
Business Wire · 09/15 20:05
Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
German diagnostics company Qiagen has agreed to develop a companion diagnostic for early-stage biotech Neuron23's inhibitor to treat Parkinson's disease. As per the new master collaboration agreement, QGEN will develop and validate...
Seekingalpha · 09/14 20:27
More
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Webull offers kinds of Qiagen NV stock information, including NYSE:QGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QGEN stock methods without spending real money on the virtual paper trading platform.